Business Context and Reporting Period
This Form 8-K is a current report filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc.) on December 13, 2022. The registrant is a Delaware corporation with principal executive offices in Lexington, MA, and its common stock trades on the Nasdaq Global Select Market under the symbol FREQ. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory disclosure rather than financial performance data.
Material Changes
There are no material financial changes reported in this document. The primary event is the disclosure of an updated corporate slide presentation regarding clinical trial timelines.
Guidance, Outlook, and Management Commentary
- Clinical Trial Update: The Company expects to disclose the results of its FX-322-208 trial in the second half of the first quarter of 2023.
- Disclosure Method: This information was communicated via an updated corporate slide presentation posted to the "Investors & Media" section of the company website.
- Legal Status of Information: The information in Item 7.01 and the attached Exhibit 99.1 is furnished, not filed, for purposes of the Exchange Act. The Company undertakes no obligation to update or amend these materials.
Investor Verification Checklist
- Verify the actual release date and data of the FX-322-208 trial results in Q1 2023.
- Review the attached Exhibit 99.1 (Corporate Slide Presentation) for additional context on the trial design and endpoints.
- Confirm the company's cash runway and liquidity status in subsequent filings (e.g., 10-Q or 10-K), as this 8-K does not contain financial data.
- Note that the information provided is not subject to the liabilities of Section 18 of the Exchange Act.